Kuros BiosciencesCSBTF 71 14-Day RSI is 14.23 as of Jul. 01, 2026. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.94 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 871 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 56.72% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Kuros Biosciences's 14-Day RSI or its related term are showing as below:
CSBTF's 14-Day RSI is ranked worse than 56.72% of 871
companies
in the Medical Devices & Instruments industry
Industry Median: 45.14
vs CSBTF: 14.23
Kuros Biosciences (OTCPK:CSBTF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Kuros Biosciences 14-Day RSI Related Terms
CSBTF vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Kuros Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's 14-Day RSI falls into.
Kuros Biosciences (OTCPK:CSBTF) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a 14-Day RSI of 14.23 as of Jul. 01, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #494 out of 871 companies in the Medical Devices & Instruments industry, placing it in the top 56.7%.
Is Kuros Biosciences' 14-Day RSI too high?
Kuros Biosciences' current 14-Day RSI is 14.23. The Medical Devices & Instruments industry median 14-Day RSI is 45.14. Kuros Biosciences' value of 14.23 is 68.5% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #494 out of 871 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #494 out of 871 companies for 14-Day RSI. This places Kuros Biosciences in the lower half of its industry. The industry median 14-Day RSI is 45.14. Kuros Biosciences' value of 14.23 is 68.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 45.14, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current 14-Day RSI of 14.23 is 68.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 45.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current 14-Day RSI is 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.94, compared to a current price of $22.72 — trading 58.6% below its estimated fair value. The current 14-Day RSI is 14.23 and 68.5% below the Medical Devices & Instruments industry median of 45.14. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 14-Day RSI is 14.23 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.6% below its estimated GF Value™ of $54.94.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
14-Day RSI: 14.23
GF Value™: $54.94 vs. price of $22.72 (58.6% below fair value)
Industry Position: 68.5% below the Medical Devices & Instruments median (#494 of 871)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 